You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDantrolene
Accession NumberDB01219  (APRD00901)
TypeSmall Molecule
GroupsApproved
DescriptionChemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Structure
Thumb
Synonyms
Dantamacrin
Dantrium
Dantrolene
Dantroleno
Dantrolenum
F-368
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dantriuminjection20 mg/60mLintravenousPar Pharmaceutical, Inc.2008-08-01Not applicableUs
Dantriumcapsule25 mg/1oralPar Pharmaceutical Inc.2008-08-01Not applicableUs
Dantriumcapsule50 mg/1oralPar Pharmaceutical Inc.2008-08-01Not applicableUs
Dantriumcapsule100 mg/1oralPar Pharmaceutical Inc.2008-08-01Not applicableUs
Dantrium Cap 100mgcapsule100 mgoralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium Cap 25mgcapsule25 mgoralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium Capsulescapsule100 mgoralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium Capsulescapsule25 mgoralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium Intravenouspowder for solution20 mgintravenousPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrolene Sodiumcapsule25 mg/1oralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Dantrolene Sodiumcapsule25 mg/1oralJHP Pharmaceuticals, LLC2013-04-08Not applicableUs
Dantrolene Sodiumcapsule50 mg/1oralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Dantrolene Sodiumcapsule50 mg/1oralJHP Pharmaceuticals, LLC2013-04-08Not applicableUs
Dantrolene Sodiumcapsule100 mg/1oralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Ryanodex Dantrolene Sodiuminjection, suspension250 mg/5mLintravenousEagle Pharmaceuticals, Inc.2014-07-23Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dantrolene Sodiumcapsule25 mg/1oralImpax Generics2005-03-01Not applicableUs
Dantrolene Sodiumcapsule25 mg/1oralAmerican Health Packaging2008-09-25Not applicableUs
Dantrolene Sodiumcapsule50 mg/1oralImpax Generics2005-03-01Not applicableUs
Dantrolene Sodiumcapsule25 mg/1oralCarilion Materials Management2005-03-01Not applicableUs
Dantrolene Sodiumcapsule100 mg/1oralImpax Generics2005-03-01Not applicableUs
Revontoinjection, powder, lyophilized, for solution20 mg/60mLintravenousUs World Meds, Llc2012-06-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DantamacrinSpepharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dantrolene Sodium
Thumb
  • InChI Key: OZOMQRBLCMDCEG-VIZOYTHASA-N
  • Monoisotopic Mass: 314.06511945
  • Average Mass: 314.253
DBSALT000397
Categories
UNIIF64QU97QCR
CAS number7261-97-4
WeightAverage: 314.253
Monoisotopic: 314.06511945
Chemical FormulaC14H10N4O5
InChI KeyInChIKey=OZOMQRBLCMDCEG-VIZOYTHASA-N
InChI
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
IUPAC Name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
SMILES
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentHydantoins
Alternative Parents
Substituents
  • Hydantoin
  • Nitrobenzene
  • Ureide
  • Benzenoid
  • Semicarbazone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Semicarbazide
  • Furan
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
PharmacodynamicsDantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that “triggering agents” (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the “triggered” malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm.
Mechanism of actionDantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.
Related Articles
AbsorptionBioavailability is 70%.
Volume of distributionNot Available
Protein bindingSignificant, mostly to albumin.
Metabolism

Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.

SubstrateEnzymesProduct
Dantrolene
Not Available
5-hydroxydantroleneDetails
Route of eliminationNot Available
Half lifeThe mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
ClearanceNot Available
ToxicityOral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9581
Caco-2 permeable-0.5587
P-glycoprotein substrateNon-substrate0.6562
P-glycoprotein inhibitor INon-inhibitor0.8977
P-glycoprotein inhibitor IINon-inhibitor0.978
Renal organic cation transporterNon-inhibitor0.8656
CYP450 2C9 substrateNon-substrate0.81
CYP450 2D6 substrateNon-substrate0.8935
CYP450 3A4 substrateSubstrate0.5848
CYP450 1A2 substrateInhibitor0.8916
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9203
CYP450 2C19 inhibitorNon-inhibitor0.8752
CYP450 3A4 inhibitorNon-inhibitor0.8985
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7676
Ames testAMES toxic0.8925
CarcinogenicityNon-carcinogens0.8732
BiodegradationReady biodegradable0.5901
Rat acute toxicity2.5390 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7215
hERG inhibition (predictor II)Non-inhibitor0.9223
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous20 mg/60mL
Capsuleoral100 mg
Capsuleoral25 mg
Powder for solutionintravenous20 mg
Capsuleoral100 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Injection, powder, lyophilized, for solutionintravenous20 mg/60mL
Injection, suspensionintravenous250 mg/5mL
Prices
Unit descriptionCostUnit
Dantrium 20 mg vial106.37USD vial
Dantrolene sodium 20 mg vial97.2USD vial
Dantrolene sodium powder17.6USD g
Dantrium 100 mg capsule2.4USD capsule
Dantrolene sodium 100 mg capsule2.03USD capsule
Dantrium 50 mg capsule1.93USD capsule
Dantrolene sodium 50 mg capsule1.63USD capsule
Dantrium 25 mg capsule1.29USD capsule
Dantrolene sodium 25 mg capsule1.09USD capsule
Dantrium 100 mg Capsule0.8USD capsule
Dantrium 25 mg Capsule0.4USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7758890 No2005-07-012025-07-01Us
US8110225 No2002-12-242022-12-24Us
US8604072 No2002-12-242022-12-24Us
US8685460 No2003-02-152023-02-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point279-280 °CDavis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.
water solubilityLow (146 mg/L)Not Available
logP1.70JANSEN,ACA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.0805 mg/mLALOGPS
logP1.65ALOGPS
logP1.26ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.23ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.73 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.87 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Davis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to
The Norwich Pharmacal Company.

General References
  1. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108 ]
External Links
ATC CodesM03CA01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (43 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dantrolene.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dantrolene.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dantrolene.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dantrolene.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dantrolene.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dantrolene.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dantrolene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dantrolene.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.
AmiodaroneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dantrolene.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.
AmoxapineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dantrolene.
AprepitantThe serum concentration of Dantrolene can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dantrolene.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene.
AtazanavirThe metabolism of Dantrolene can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dantrolene.
AzelastineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dantrolene.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dantrolene.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dantrolene.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dantrolene.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dantrolene.
BexaroteneThe serum concentration of Dantrolene can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Dantrolene can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Dantrolene can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dantrolene can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
BrimonidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dantrolene.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dantrolene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Dantrolene.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dantrolene.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dantrolene.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dantrolene.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dantrolene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dantrolene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dantrolene.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.
CeritinibThe serum concentration of Dantrolene can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dantrolene.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dantrolene.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dantrolene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dantrolene.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dantrolene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dantrolene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dantrolene.
CitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.
ClarithromycinThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Dantrolene can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dantrolene.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dantrolene.
ClomipramineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dantrolene.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.
ClotrimazoleThe metabolism of Dantrolene can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.
CobicistatThe metabolism of Dantrolene can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dantrolene.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.
ConivaptanThe serum concentration of Dantrolene can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Dantrolene can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.
CyclosporineThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.
DabrafenibThe serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dantrolene.
DapoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapoxetine.
DarunavirThe metabolism of Dantrolene can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Dantrolene can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dantrolene.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dantrolene.
DexamethasoneThe serum concentration of Dantrolene can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Dantrolene.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dantrolene.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dantrolene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dantrolene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dantrolene.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dantrolene.
DifenoxinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.
DihydroergotamineThe metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dantrolene.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dantrolene.
DiltiazemThe metabolism of Dantrolene can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dantrolene.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.
DoxycyclineThe metabolism of Dantrolene can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DoxylamineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dantrolene.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
DronedaroneThe metabolism of Dantrolene can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Dantrolene.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dantrolene.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dantrolene.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dantrolene.
EfavirenzThe serum concentration of Dantrolene can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Dantrolene is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dantrolene.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.
EnzalutamideThe serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Dantrolene can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Dantrolene can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dantrolene.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.
EthanolDantrolene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Dantrolene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dantrolene.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dantrolene.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dantrolene.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dantrolene.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dantrolene.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dantrolene.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dantrolene.
EtoperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dantrolene.
EtravirineThe serum concentration of Dantrolene can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dantrolene.
FenfluramineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dantrolene.
FlibanserinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.
FluconazoleThe metabolism of Dantrolene can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dantrolene.
FlunarizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dantrolene.
FluoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dantrolene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dantrolene.
FluvoxamineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluvoxamine.
FluvoxamineThe metabolism of Dantrolene can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Dantrolene can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dantrolene can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dantrolene.
Fusidic AcidThe serum concentration of Dantrolene can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dantrolene is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dantrolene.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dantrolene.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dantrolene.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dantrolene.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dantrolene.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dantrolene.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dantrolene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
HydroxyzineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Hydroxyzine.
IdelalisibThe serum concentration of Dantrolene can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.
ImatinibThe metabolism of Dantrolene can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.
IndalpineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indalpine.
IndinavirThe metabolism of Dantrolene can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Dantrolene can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dantrolene.
IsradipineThe metabolism of Dantrolene can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Dantrolene can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Dantrolene can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dantrolene.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dantrolene.
KetoconazoleThe metabolism of Dantrolene can be decreased when combined with Ketoconazole.
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dantrolene.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Dantrolene.
LevocetirizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dantrolene.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dantrolene.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dantrolene.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dantrolene.
LopinavirThe metabolism of Dantrolene can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dantrolene.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.
LovastatinThe metabolism of Dantrolene can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.
Lu AA21004The risk or severity of adverse effects can be increased when Dantrolene is combined with Lu AA21004.
LuliconazoleThe serum concentration of Dantrolene can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Dantrolene is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dantrolene.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dantrolene.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dantrolene.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dantrolene.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dantrolene.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dantrolene.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dantrolene.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dantrolene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dantrolene.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dantrolene.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dantrolene.
MethsuximideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dantrolene.
MetyrosineDantrolene may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.
MifepristoneThe metabolism of Dantrolene can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
MirtazapineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dantrolene.
MitotaneThe serum concentration of Dantrolene can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Dantrolene can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dantrolene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.
NabiloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Nabilone.
NafcillinThe serum concentration of Dantrolene can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.
NefazodoneThe metabolism of Dantrolene can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Dantrolene can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Dantrolene can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Dantrolene can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Dantrolene can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dantrolene.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dantrolene.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.
OlanzapineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Olanzapine.
OlaparibThe metabolism of Dantrolene can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dantrolene.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dantrolene.
OrphenadrineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Dantrolene.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dantrolene.
OsimertinibThe serum concentration of Dantrolene can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dantrolene.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dantrolene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.
PalbociclibThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.
ParaldehydeDantrolene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Dantrolene.
ParoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dantrolene.
PerampanelThe risk or severity of adverse effects can be increased when Dantrolene is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dantrolene.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Dantrolene.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dantrolene.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Dantrolene.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dantrolene.
PipotiazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.
PosaconazoleThe metabolism of Dantrolene can be decreased when combined with Posaconazole.
PramipexoleDantrolene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dantrolene.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dantrolene.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dantrolene.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dantrolene.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Dantrolene.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dantrolene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dantrolene.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dantrolene.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dantrolene.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.
RanolazineThe metabolism of Dantrolene can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.
RifabutinThe metabolism of Dantrolene can be increased when combined with Rifabutin.
RifampicinThe metabolism of Dantrolene can be increased when combined with Rifampicin.
RifapentineThe metabolism of Dantrolene can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.
RitonavirThe metabolism of Dantrolene can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dantrolene.
RopiniroleDantrolene may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene.
RotigotineDantrolene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dantrolene.
SaquinavirThe metabolism of Dantrolene can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dantrolene.
SertralineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.
SildenafilThe metabolism of Dantrolene can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Dantrolene can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dantrolene can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Dantrolene.
St. John's WortThe serum concentration of Dantrolene can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.
SulfisoxazoleThe metabolism of Dantrolene can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dantrolene.
SuvorexantThe risk or severity of adverse effects can be increased when Dantrolene is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tasimelteon.
TelaprevirThe metabolism of Dantrolene can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Dantrolene can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.
TetrabenazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dantrolene.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dantrolene.
ThalidomideDantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Dantrolene.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dantrolene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dantrolene.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.
TiclopidineThe metabolism of Dantrolene can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dantrolene.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.
TocilizumabThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dantrolene.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.
TrazodoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dantrolene.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dantrolene.
VecuroniumDantrolene may increase the neuromuscular blocking activities of Vecuronium.
VenlafaxineThe metabolism of Dantrolene can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Dantrolene can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dantrolene.
VilazodoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vilazodone.
VoriconazoleThe metabolism of Dantrolene can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dantrolene.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.
ZiconotideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zimelidine.
ZiprasidoneThe metabolism of Dantrolene can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dantrolene.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Dantrolene.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dantrolene.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dantrolene.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores ...
Gene Name:
RYR1
Uniprot ID:
P21817
Molecular Weight:
565170.715 Da
References
  1. Britt BA, Scott E, Frodis W, Clements MJ, Endrenyi L: Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle. Can Anaesth Soc J. 1984 Mar;31(2):130-54. [PubMed:6704779 ]
  2. Harrison GG: Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975. Br J Anaesth. 1998 Oct;81(4):626-9; discussion 625. [PubMed:9924249 ]
  3. Flewellen EH, Nelson TE: Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Anesthesiology. 1980 Apr;52(4):303-8. [PubMed:7362049 ]
  4. Tonner PH, Scholz J, Richter A, Loscher W, Steinfath M, Wappler F, Wlaz P, Hadji B, Roewer N, Schulte am Esch J: Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. Br J Anaesth. 1995 Oct;75(4):467-71. [PubMed:7488490 ]
  5. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J: Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem. 2006 Nov 3;281(44):33477-86. Epub 2006 Aug 31. [PubMed:16945924 ]
  6. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108 ]
  7. Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F: [Dantrolene. Pharmacological and therapeutic aspects]. Anaesthesist. 2003 Mar;52(3):238-45. [PubMed:12666006 ]
  8. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002 Sep 20;277(38):34918-23. Epub 2002 Jul 11. [PubMed:12167662 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:15